Table 1.
The basic information and data of all included studies in the meta-analysis
| Author | Year | Country | No. of patients | Sex (M/F) | Tumor type | Age (years) Median (range) |
Cut-off value | Survival analysis | Treatment | NOS score |
|---|---|---|---|---|---|---|---|---|---|---|
| Kim | 2015 | Korea | 277 | 218/59 | UTUC | 63.7 (29.5–90) | 150 | CSS, DFS | NUx | 7 |
| Zhang | 2015 | China | 124 | 100/24 | BC | 65 (30–78) | 140 | OS | RC | 8 |
| Song | 2016 | China | 140 | 86/54 | UTUC | 67 (39–81) | 128 | DFS, PFS | RNU | 6 |
| Altan | 2017 | Turkey | 113 | 86/27 | UTUC | 63.7 | 150 | DFS, PFS | RNU | 7 |
| Dalpiaz | 2017 | Austria | 180 | 109/71 | UTUC | 70 | 150 | OS, PFS | RNU | 8 |
| Huang | 2017 | China | 481 | 311/170 | UTUC | 65 (30–89) | 241 | OS, PFS | RNU | 7 |
| Kang | 2017 | Korea | 1551 | 1302/249 | BC | 65 (57–72) | 124 | OS, CSS | TURB | 7 |
| Mao | 2017 | China | 207 | 169/38 | BC | 66 (59–80) | 123 | DFS, PFS | TURB | 8 |
| Miyake | 2017 | Japan | 117 | 95/22 | BC | 72 | 150 | OS, CSS | RC | 8 |
| Rajwa | 2018 | Poland | 144 | NA | BC | NA | 161 | OS, CSS | RC | 6 |
| Son | 2018 | Korea | 1137 | 825/312 | UTUC | 69 | 142 | DFS, PFS | RNU | 6 |
| Itami | 2019 | Japan | 125 | 96/29 | UTUC | 72 (38–90) | 150 | OS, DFS | NUx | 7 |
| Kuroda | 2019 | Japan | 187 | 138/49 | UTUC | 71 (38–90) | 165 | DFS, PFS | RNU | 7 |
| Yuk | 2019 | Korea | 385 | 327/58 | BC | 72.6 | 171 | OS, CSS | TURB | 7 |
| Zhu | 2019 | China | 186 | 157/29 | BC | 65 | 111 | OS | RC | 7 |
OS overall survival, DFS disease-free survival, PFS progression-free survival, CSS cancer-specific survival, NUx nephroureterectomy, RC radical cystectomy, RNU radical nephroureterectomy, TURB transurethral resection of bladder tumor, NA not available, NOS Newcastle–Ottawa Scale, UTUC upper tract urothelial carcinoma, BC bladder cancer